发明申请
- 专利标题： ANTIBODIES TO MODIFIED HUMAN IGF-1/E PEPTIDES
- 专利标题（中）： 改良人IGF-1 / E肽的抗体
-
申请号： US13128335申请日： 2009-11-10
-
公开(公告)号： US20110218145A1公开(公告)日： 2011-09-08
- 发明人: Mara Fornaro , John Xu , Yuan Gao , Rainer Hillenbrand , Francois Legay , Daniela Stoellner
- 申请人： Mara Fornaro , John Xu , Yuan Gao , Rainer Hillenbrand , Francois Legay , Daniela Stoellner
- 申请人地址： CH Basel
- 专利权人： NOVARTIS AG
- 当前专利权人： NOVARTIS AG
- 当前专利权人地址： CH Basel
- 国际申请： PCT/EP2009/064947 WO 20091110
- 主分类号： A61K38/30
- IPC分类号： A61K38/30 ; C07K16/00 ; C12N5/16 ; C07K7/06 ; C07H21/00 ; C12N15/63 ; G01N33/53 ; C07K14/575 ; C12N5/10 ; A61P21/00
摘要：
High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.
公开/授权文献
- US08753632B2 Antibodies to modified human IGF-1/E peptides 公开/授权日：2014-06-17
信息查询
IPC分类:
